This is a working overview of Visceral adiposity, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-20 and is reviewed periodically as new material appears.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Routine purity assay | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Liquid chromatography–mass spectrometry | Mass shift reveals modification or truncation |
| Typical purity specification | Greater than 95 percent | Reported as main-peak area percentage |
| Long-term storage | Minus 20 degrees Celsius or colder | Sealed, protected from light |
| Principal degradation routes | Oxidation, deamidation, aggregation | Monitored individually during stability studies |
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
== Fungi == Fungi can be used for many of the same processes as bacteria. For industrial applications, yeasts combine the bacterial advantages of being a single-celled organism that is easy to manipulate and grow with the advanced protein modifications found in eukaryotes. They can be used to produce large complex molecules for use in food, pharmaceuticals, hormones, and steroids. Yeast is important for wine production and as of 2016 two genetically modified yeasts involved in the fermentation of wine have been commercialized in the United States and Canada. One has increased malolactic fermentation efficiency, while the other prevents the production of dangerous ethyl carbamate compounds during fermentation. There have also been advances in the production of biofuel from genetically modified fungi. Fungi, being the most common pathogens of insects, make attractive biopesticides. Unlike bacteria and viruses they have the advantage of infecting the insects by contact alone, although they are out competed in efficiency by chemical pesticides. Genetic engineering can improve virulence, usually by adding more virulent proteins, increasing infection rate or enhancing spore persistence. Many of the disease carrying vectors are susceptible to entomopathogenic fungi. An attractive target for biological control are mosquitos, vectors for a range of deadly diseases, including malaria, yellow fever and dengue fever.
While most heme proteins are attached to the prosthetic group through iron ion ligation and tertiary interactions, the heme group of cytochrome c makes thioether bonds with two cysteine side chains of the protein. One of the main properties of heme c, which allows cytochrome c to have variety of functions, is its ability to have different reduction potentials in nature. This property determines the kinetics and thermodynamics of an electron transfer reaction.
The James Madison Memorial Building is located between First and Second Streets on Independence Avenue SE. The building was constructed from 1971 to 1976, and serves as the official memorial to James Madison, a Founding Father and the fourth President of the United States. The Madison Building is also home to the United States Copyright Office and to the Mary Pickford Theater, the "motion picture and television reading room" of the Library of Congress. The theater hosts regular free screenings of classic and contemporary movies and television shows.
==== Systemic lupus erythematosus ==== Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Studies have implicated a role for neutrophil death (NETosis) in SLE. Neutrophil ferroptosis is prevalent in patients with SLE and is induced by autoantibodies and interferon-alpha (IFN-α), which suppress GPX4 expression via the transcriptional repressor CREMα. Inhibition of ferroptosis was able to ameliorate SLE disease progression in the MRL/lpr mouse model of SLE.
Sources: en.wikipedia.org
In August 1935, Albert Rowe, secretary of the Tizard Committee, coined the term "Radio Direction and Finding" (RDF), deliberately choosing a name that could be confused with "Radio Direction Finding", a term already in widespread use. In a 9 September 1935 memo, Watson-Watt outlined the progress to date. At that time the range was about 40 mi (64 km), so Watson-Watt suggested building a complete network of stations 20 mi (32 km) apart along the entire east coast. Since the transmitters and receivers were separate, to save development costs he suggested placing a transmitter at every other station. The transmitter signal could be used by a receiver at that site as well as the ones on each side of it. This was quickly rendered moot by the rapid increases in range. When the Committee next visited the site in October, the range was up to 80 mi (130 km), and Wilkins was working on a method for height finding using multiple antennas. In spite of its ad hoc nature and short development time of less than six months, the Orfordness system had already become a useful and practical system. In comparison, the acoustic mirror systems that had been in development for a decade were still limited to only 5 mi (8.0 km) range under most conditions, and were very difficult to use in practice. Work on mirror systems ended, and on 19 December 1935, a £60,000 contract for five RDF stations along the south-east coast was sent out, to be operational by August 1936. The only person not convinced of the utility of RDF was Lindemann.
He believed that some of the effects of increased CO2 levels are favourable and not taken into account by climate scientists, such as increased agricultural yield, and further that the positive benefits of CO2 likely outweigh the negative effects. He was skeptical about the simulation models used to predict climate change, arguing that political efforts to reduce causes of climate change distract from other global problems that should take priority. He was awarded the 1996 Lewis Thomas Prize and the 2000 Templeton Prize. He said that "As we look out into the Universe and identify the many accidents of physics and astronomy that have worked together to our benefit, it almost seems as if the Universe must in some sense have known that we were coming."
===== MeSH D08.811.682.664 – oxidoreductases acting on ch-nh2 group donors ===== MeSH D08.811.682.664.249 – amine oxidase (copper-containing) MeSH D08.811.682.664.500 – amino acid oxidoreductases MeSH D08.811.682.664.500.062 – alanine dehydrogenase MeSH D08.811.682.664.500.125 – d-amino-acid oxidase MeSH D08.811.682.664.500.261 – d-aspartate oxidase MeSH D08.811.682.664.500.398 – glutamate dehydrogenase MeSH D08.811.682.664.500.410 – glutamate dehydrogenase (nadp+) MeSH D08.811.682.664.500.470 – glutamate synthase (NADPH) MeSH D08.811.682.664.500.484 – glutamate synthase (NADH) MeSH D08.811.682.664.500.498 – glycine decarboxylase complex MeSH D08.811.682.664.500.498.500 – glycine dehydrogenase (decarboxylating) MeSH D08.811.682.664.500.526 – glycine dehydrogenase MeSH D08.811.682.664.500.677 – l-amino acid oxidase MeSH D08.811.682.664.500.724 – leucine dehydrogenase MeSH D08.811.682.664.500.772 – nitric oxide synthase MeSH D08.811.682.664.500.772.249 – nitric oxide synthase type i MeSH D08.811.682.664.500.772.500 – nitric oxide synthase type ii MeSH D08.811.682.664.500.772.750 – nitric oxide synthase type iii MeSH D08.811.682.664.500.810 – proline oxidase MeSH D08.811.682.664.500.848 – protein-lysine 6-oxidase MeSH D08.811.682.664.500.924 – valine dehydrogenase (NADP+) MeSH D08.811.682.664.750 – monoamine oxidase MeSH D08.811.682.664.750.100 – benzylamine oxidase
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.
Removing water slows hydrolysis and limits the mobility that drives aggregation. A dry powder is also less hospitable to microbial growth. These factors make cold storage of the solid form more forgiving than storage of a reconstituted solution.
Methionine oxidation, asparagine and glutamine deamidation, and non-covalent or covalent aggregation are the main routes reported for peptides of this class. Each is tracked as a separate impurity. Their relative abundance depends on formulation and storage history.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.